Fundraising Fox
X-Therma Inc.
Richmond, US · Founded 2014 · Delaware corporation · 31 employees on LinkedIn · 10 known investors
Find your way into X-Therma Inc.
Sign up to see every warm intro you have to X-Therma Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the X-Therma Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics. Its products, including the XT-ViVo preservation solution and TimeSeal organ transport device, target organ and biologic preservation for transplantation.
Founders & leadership
X-Therma Inc. was founded in 2014 by Xiaoxi Wei and Mark Kline.
XW
Xiaoxi WeiFounder & CEOXiaoxi Wei is founder and CEO of X-Therma, which develops peptoid-based cryopreservation technology for long-term sub-zero storage and transport of cells, tissues, organs, and biologics for transplantation and regenerative medicine applications.
MK
Mark KlineCo-founder · Chief Technology Officer and Chief Operating OfficerMark Kline is co-founder and operating and technical lead of X-Therma, a company developing peptoid-based preservation solutions for cells, tissues, and organs. He holds a PhD in Medicinal Chemistry from SUNY-Buffalo, completed postdoctoral research on peptoids at Lawrence Berkeley National Laboratory, and has directed over $14 million in government research funding from agencies including the NIH, NSF, and DOD.
JW
Johannes WeggemannNamed on SEC filing
Investors · 10
Dellin Investmentslisted by Dellin InvestmentsPhiladelphia
How we know: Dellin Investments's portfolio page · Not right? Tell us
Methuselah Foundationlisted by Methuselah FoundationSpringfield
How we know: Methuselah Foundation's portfolio page · Not right? Tell us
VU Venture Partnerslisted by VU Venture PartnersSan Francisco · $200K – $1M
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 2
LOREA AGStarling Locke Capitallead
Reported raises · per SEC filings
Form D private placements$35.4M disclosed across 3 rounds · 2021–2024
▶$22.4MraisedMar 2024 · 39 investors · BiotechnologyRule 506(b)
▶$22.4MraisedMar 2024 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Johannes WeggemannExecutive Officer, Director
- Xiaoxi WeiExecutive Officer, Director
- Mark KlineExecutive Officer, Director
- James GreenwoodDirector
- Offering amount
- $22.4M
- Amount sold
- $22.4M
- Minimum investment
- $20K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedDec 2021 · 20 investors · BiotechnologyRule 506(b)
▶$2.6MraisedDec 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark KlineExecutive Officer, Director
- Xiaoxi WeiExecutive Officer, Director
- Johannes WeggemannDirector
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $10.4K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.4MraisedNov 2021 · 20 investors · BiotechnologyRule 506(b)
▶$10.4MraisedNov 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Johannes WeggemannDirector
- Xiaoxi WeiExecutive Officer, Director
- Mark KlineExecutive Officer, Director
- Offering amount
- $10.4M
- Amount sold
- $10.4M
- Minimum investment
- $25K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
nChroma BionChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ExThera Medical
XmtherapeuticsXM Therapeutics develops extracellular matrix-based therapies to treat patients with chronic disorders, with initial applications targeting heart failure and pulmonary fibrosis. The company is based in Providence, Rhode Island and leverages partnerships with Brown University for research and development.
Companies working in the same space as X-Therma Inc..
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $971.2K |
| National Science Foundation | Phase II | 2018 | $743.3K |
| U.S. ArmyArmy | Phase II | 2017 | $999.8K |
| Department of DefenseDefense Health Program | Phase II | 2017 | $999K |
| U.S. ArmyArmy | Phase I | 2017 | $149.9K |
| Department of DefenseDefense Health Program | Phase II | 2016 | $999.9K |
| National Science Foundation | Phase I | 2016 | $225K |
| Department of DefenseDefense Health Program | Phase I | 2016 | $154.6K |
| Department of DefenseDefense Health Program | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does X-Therma Inc. do?
- X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics. Its products, including the XT-ViVo preservation solution and TimeSeal organ transport device, target organ and biologic preservation for transplantation.
- Who founded X-Therma Inc.?
- X-Therma Inc. was founded by Xiaoxi Wei, Mark Kline in 2014.
- Who are X-Therma Inc.'s investors?
- X-Therma Inc.'s investors include Aurum Venture Partners, Dellin Investments, LIFTT, Methuselah Foundation, Methuselah Funds, Portfolia, VU Venture Partners, Zen11 Holding.
- How much funding has X-Therma Inc. raised?
- X-Therma Inc. has disclosed $35.4M raised across 3 rounds.
- Where is X-Therma Inc. headquartered?
- X-Therma Inc. is headquartered in Richmond, US.